ArticleAnnals of medicine and surgery (2012)2025
Usefulness of the Fibrosis-3 index in patients with hepatitis C.
Article in Annals of medicine and surgery (2012), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: Noninvasive liver fibrosis prediction scores are crucial for evaluating liver disease progression. It was previously reported that the newly proposed Fibrosis-3 index (FIB-3 index) is useful in cases of metabolic dysfunction-associated steatotic liver disease. In this study, we investigated whether it is useful in cases of hepatitis C, a viral liver disease. Methods: We evaluated the liver fibrosis prediction ability of both the FIB-3 and FIB-4 indices by age-group in 517 patients with treatment-naïve hepatitis C who underwent liver biopsy. Results: The FIB-3 and FIB-4 indices linearly increased with fibrosis progression in patients with hepatitis C virus infection. Receiver operating characteristic analysis revealed no significant difference between the two indices in predicting advanced fibrosis (≥F3) and moderate fibrosis (≥F2). The FIB-3 index showed significantly higher accuracy (47.8%) in predicting advanced fibrosis in patients aged ≥70 years than the FIB-4 index (28.3%) using a single cutoff value derived from the Youden index for the entire cohort. Conclusions: The FIB-3 index proved useful for predicting liver fibrosis and prognosis in patients with hepatitis C, with performance comparable to that of the FIB-4 index. Moreover, its ability to use a single cutoff value across age-groups may offer a clinical advantage.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.